European Journal of Clinical Pharmacology

, Volume 73, Issue 7, pp 837–842 | Cite as

Association between CACNA1C gene polymorphisms and ritodrine-induced adverse events in preterm labor patients

  • Min Young Baek
  • Han Sung Hwang
  • Jin Young Park
  • Jee Eun Chung
  • Kyung Eun Lee
  • Gwan Yung Lee
  • Jin Won Seong
  • Jeong Yee
  • Young Ju KimEmail author
  • Hye Sun GwakEmail author



As a tocolytic agent, ritodrine has been used in European and Asian countries but has lost popularity due to safety concerns. This study aimed to investigate the relationship between adverse drug events caused by ritodrine and the CACNA1C polymorphisms in preterm labor patients.


Data were collected from medical records including maternal age, gestational age, body mass index, dilation score, effacement score, modified Bishop score, maximum infusion rate, and adverse drug events. Five single-nucleotide polymorphisms of the CACNA1C gene (rs10774053, rs215994, rs215976, rs2239128, and rs2041135) were analyzed.


One hundred eighty-six patients were included, 33 of whom had adverse drug events. A allele carriers of rs10774053 showed about 0.293-fold lower adverse drug events than GG genotype carriers (p = 0.012, absolute risk reduction = 16.5%) after adjusting for other confounding variables; the number needed to genotype for preventing one patient with GG genotype from suffering higher incidence of adverse drug events was calculated to be 14.6. Increase in maximum infusion rate of 1 mL/h was associated with a 1.03-fold (95% CI 1.01~1.06, p = 0.005) increased risk of adverse drug events. None of the patients with a CC genotype of rs215994 had adverse drug events, whereas 22.1% of the T allele carriers had adverse drug events.


This study showed that CACNA1C gene polymorphisms could alter the probability of adverse drug event risk when ritodrine is used in preterm labor.


Ritodrine CACNA1C Polymorphism Adverse drug events Preterm labor patients 


Compliance with ethical standards


This work was supported by a grant from the Korea Health Industry Development Institute (KHIDI) (No. HI14C0306), funded by the Ministry of Health and Welfare, Republic of Korea.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Beck S, Wojdyla D, Say L, Betran AP, Merialdi M, Requejo JH et al (2010) The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ 88:31–38CrossRefPubMedGoogle Scholar
  2. 2.
    Blencowe H, Cousens S, Chou D, Oestergaard M, Say L, Moller AB et al (2013) Born too soon: the global epidemiology of 15 million preterm births. Reprod Health 10:S2CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    National Health Insurance Service.
  4. 4.
    Tsatsaris V, Cabrol D, Carbonne B (2004) Pharmacokinetics of tocolytic agents. Clin Pharmacokinet 43:833–844CrossRefPubMedGoogle Scholar
  5. 5.
    Schleussner E (2013) The prevention, diagnosis and treatment of premature labor. Dtsch Arztebl Int 110:227–235PubMedPubMedCentralGoogle Scholar
  6. 6.
    The Canadian Preterm Labor Investigators Group (1992) Treatment of preterm labor with the beta-adrenergic agonist ritodrine. N Engl J Med 327:308–312CrossRefGoogle Scholar
  7. 7.
    Tulumbaci O, Onan MA, Turkoglu S, Kurdoglu M, Boyaci B, Tiras MB (2007) Effects of ritodrine hydrochloride tocolysis on echocardiographic parameters. J Matern Fetal Neonatal Med 20:751–755CrossRefPubMedGoogle Scholar
  8. 8.
    Osterrieder W, Brum G, Hescheler J, Trautwein W, Flockerzi V, Hofmann F (1982) Injection of subunits of cyclic AMP-dependent protein kinase into cardiac myocytes modulates Ca2+ current. Nature 298:576–578CrossRefPubMedGoogle Scholar
  9. 9.
    Mcdonald TF, Pelzer S, Trautwein W, Pelzer DJ (1994) Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol Rev 74:365–507PubMedGoogle Scholar
  10. 10.
    Modell SM, Lehmann MH (2006) The long QT syndrome family of cardiac ion channelopathies: a HuGE review. Genet Med 8:143–155CrossRefPubMedGoogle Scholar
  11. 11.
    Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK (1998) Adverse drug reactions. BMJ 316:1295–1298CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hui Y, Liu MC (2015) Sulfation of ritodrine by the human cytosolic sulfotransferases (SULTs): effects of SULT1A3 genetic polymorphism. Eur J Pharmacol 761:125–129CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Park JY, Lee NR, Lee KE, Park S, Kim YJ, Gwak HS (2014) Effects of beta2-adrenergic receptor gene polymorphisms on ritodrine therapy in pregnant women with preterm labor: prospective follow-up study. Int J Mol Sci 15:12885–12894CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM et al (2002) The human genome browser at UCSC. Genome Res 12:996–1006CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Resource Coordinators NCBI (2016) Database resources of the National Center for biotechnology information. Nucleic Acids Res 44:D7–19CrossRefGoogle Scholar
  16. 16.
    Ward LD, Kellis M (2012) HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 40:D930–D934CrossRefPubMedGoogle Scholar
  17. 17.
    Wray S (1993) Uterine contraction and physiological mechanisms of modulation. Am J Phys 264:C1–18Google Scholar
  18. 18.
    Wray S, Jones K, Kupittayanant S, Li Y, Matthew A, Monir-Bishty E et al (2003) Calcium signaling and uterine contractility. J Soc Gynecol Investig 10:252–264CrossRefPubMedGoogle Scholar
  19. 19.
    Hennessey JA, Boczek NJ, Jiang YH, Miller JD, Patrick W, Pfeiffer R et al (2014) A CACNA1C variant associated with reduced voltage-dependent inactivation, increased CaV1.2 channel window current, and arrhythmogenesis. PLoS One 9:e106982CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Burashnikov E, Pfeiffer R, Barajas-Martinez H, Delpón E, Hu D, Desai M et al (2010) Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm 7:1872–1882CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Beitelshees AL, Navare H, Wang D, Gong Y, Wessel J, Moss JI et al (2009) CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet 2:362–370CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Bremer T, Man A, Kask K, Diamond C (2006) CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension. Pharmacogenomics 7:271–279CrossRefPubMedGoogle Scholar
  23. 23.
    Mangoni AA, Jackson SH (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6–14CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Shi S, Klotz U (2011) Age-related changes in pharmacokinetics. Curr Drug Metab 12:601–610CrossRefPubMedGoogle Scholar
  25. 25.
    Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49:71–87CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.College of Pharmacy & Division of Life and Pharmaceutical SciencesEwha Womans UniversitySeoulRepublic of Korea
  2. 2.Department of Obstetrics and Gynecology, Konkuk University Medical CenterKonkuk University School of MedicineSeoulRepublic of Korea
  3. 3.College of PharmacySungkyunkwan UniversitySuwon-siRepublic of Korea
  4. 4.College of PharmacyChungbuk National UniversityCheongjuRepublic of Korea
  5. 5.Department of Obstetrics and GynecologyEwha Womans University School of MedicineSeoulRepublic of Korea

Personalised recommendations